• Respiratory syncytial virus (RSV) is a seasonal virus infection that can cause severe lower respiratory infection
   
• The vaccine candidate can induce antibodies capable of neutralizing the virus

Virometix, a private Swiss biotech firm involved in the development of new-gen immunotherapeutic drugs and vaccines to prevent and treat oncology and other infectious diseases, recently announced that the company’s first application in human clinical trial of Phase 1 study of respiratory syncytial virus (RSV) vaccine, also called V-306, among healthy volunteers, has received approval by FAMHP, the Belgian health Authority.

The company has secured its funding and the activities are underway to begin the trial in the forthcoming days.

Apparently, RSV is essentially a seasonal virus infection and is known as the most common reason for a severe lower respiratory infection. Young children, infants along with elderly and immunocompromised population have the risk to get the infection. There has been no vaccine that has received approval to prevent the RSV infection yet. The growth opportunity for the RSV market has been estimated to be valued at $5.4 billion by the year 2028.

Virometix Chief Executive Officer, Anna Sumeray stated that the company is looking forward to entering the trial of V-306. There had been several efforts taken over the span of few years to advance the new Synthetic Virus-like Particle platform, also called SVLP, which has led to the development of a vaccine candidate harboring a probability to secure susceptible patients from the mortality and morbidity that is related with RSV infection. The company will be generating its first clinical data by another few months.

Virometix’s Scientific Advisor, Professor Paul-Henri Lambert from the Centre of Vaccinology at the Department of Pathology and Immunology, Geneva University, stated that he is looking forward to the major SVLP technology as well as its capability to stimulate a secure immune response effectively and without any need for adjuvants.

V-306 is capable of inducing certain antibodies that are famous for neutralizing the virus. He further added that the company will await the results of the Phase 1 study.

Source Credit- https://www.virometix.com/downloads/Virometix-AG-press-release-V-306-final-12March2020.pdf